What are the latest developments in stem cells and regenerative medicine in this first week of 2017 and right before the end of the past year? Here are some of the headlines and papers that have popped up that seem notable or surprising. Be sure to also check out our stem cell & regenerative medicine meeting hub for 2017.
Each year I make a list of predictions for the stem cell and regenerative medicine field for the coming new year. Later in this post I list my top 20 stem cell predictions for 2017. In looking at my past predictions I realized this will now be my 7th year doing stem cell/regenerative medicine yearly predictions.
You can see below links to these predictions for past years, which sometimes seems rather far removed from today and in other cases strike me as strangely apropos of our times.
Our President-elect recently released his health care policy agenda and it looks like the FDA is a target in terms of reducing oversight. Over at the Washington Post, Carolyn Johnson has a nice articleon this development.
One point in the agenda in particular has caught people’s attention as potentially the key indicator of what is to come for regulatory oversight of biomedical products:
“Reform the Food and Drug Administration, to put greater focus on the need of patients for new and innovative medical products”
This one sentence says a great deal in terms of signaling that Trump wants dramatically less oversight or at least that’s how “reform” is being interpreted.
For those of us in the stem cell field this sentence from Trump sounds very reminiscent of language from proponents of reduced regulation and even stem cell clinics, who say they are just in it for the patients but keep keeping racking up profits.
This signal from Trump does not bode well for stem cell and regenerative medicine oversight in the coming years, but we’ll have to stay tuned to see how this develops.